Navigation Links
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Date:10/27/2011

EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2011.

In the third quarter of 2011, we:

  • Achieved a record $143 million in net product sales, representing 21 percent growth over the third quarter of 2010;
  • Recorded $65 million in net sales of Cinryze for the third quarter and $184 million for the 9 month period,  representing Cinryze growth of 33 percent and 48 percent respectively, over the same periods in 2010;
  • Realized non-GAAP adjusted net income of $48 million; GAAP net income reached $28 million;
  • Generated net cash from operations of $53 million;
  • Initiated a Phase 2 study to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with rHuPH20;
  • Commenced the launch of Cinryze in Europe;
  • Attained centralized European Pediatric Use Marketing Authorization (PUMA) for Buccolam for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents from age 3 months to less than 18 years of age;
  • Entered into a licensing agreement with Intellect Neurosciences, Inc. (OTCBB: ILNS) to acquire the worldwide rights to the clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia;
  • Repurchased an additional 5.5 million shares at a cost of approximately $98.9 million that substantially completed the $150 million securities repurchase program, and announced an additional $200 million buyback program;
  • Maintained a working capital of $532 million as of September 30, 2011, including cash, cash equivalents and short-term investments of $460 million; and
  • Entered into a $200 million, 3-year, senior secured, revolving credit facility.

  • "In all aspects of
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
    2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
    3. ViroPharma Announces Additional Securities Repurchase Program
    4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
    6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
    7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
    8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
    9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
    10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
    11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)...  NeuroSigma, Inc. (NeuroSigma), a California ... non-invasive Monarch ™ eTNS™ Therapy for ... that enrollment has begun in a pediatric open label ... therapy for the treatment of Lennox-Gastaut Syndrome (LGS). ... View-UCLA Medical Center in Sylmar, California ...
    (Date:7/22/2014)... , July 22, 2014 ... device company focused on solid dose formulations of ... solid formulation of octreotide acetate achieved successful results ... the currently marketed liquid product (Sandostatin®).  Based on ... formulation production process to a contract manufacturing organisation ...
    (Date:7/21/2014)... , July 21, 2014  Champions Oncology (OTC: ... technology solutions and services to personalize the development and ... its financial and operational results for the fourth quarter ... July 24, 2014, after market close. The ... results that day at 4:30 p.m. EDT (1:30 p.m. ...
    Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
    ... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Valacyclovir Hydrochloride Tablets, 500 mg (base) and 1000 mg ... for the herpes virus infection. The product is being ...
    ... National Anesthesia Services, Inc. celebrates its 21st anniversary as one of ... a locum tenens and permanent basis in hospitals, surgery centers and medical ... , , ... when we first began," said president and owner Stephen Read . ...
    Cached Medicine Technology:Mylan Receives Approval for Generic Version of Valtrex® 2National Anesthesia Services, Inc. Celebrates 21 Years of Dynamic Growth and Achievement 2
    (Date:7/22/2014)... July 22, 2014 According to a ... care, Automobile, Aerospace & Defense, Marine and Mining) & ... East, and Rest of the world) - Forecast Analysis ... expected to grow at a CAGR 8.00% to reach ... is estimated to grow at a CAGR of 6.00% ...
    (Date:7/22/2014)... Carlsbad, CA (PRWEB) July 22, 2014 ... 0% financing for 24 months on all models during ... 18th-28th. , Please visit http://www.d1spas.com/financing for ... leader in hydrotherapy, Dimension One Spas offers a wide ... your fingertips including lights, fountains, waterfalls, music, customizable massage, ...
    (Date:7/22/2014)... -- People who suffer long-term sleep problems after a ... pressure, a new study suggests. Previous research has ... death, but few studies have examined the reasons for ... causes, according to the University of Arizona investigators. ... or divorced for about 16 weeks. They reported on ...
    (Date:7/22/2014)... a five-year, $3 million grant to study how ... maltreatment during childhood leave molecular marks in DNA ... The Center for Biomarker Research and Personalized Medicine ... with Duke University School of Medicine, will conduct ... National Institutes of Health, National Institute of Mental ...
    (Date:7/22/2014)... Belmont, CA (PRWEB) July 22, 2014 ... and publisher for women, this year celebrates its tenth ... Silicon Valley. Thousands of attendees, including community leaders from ... sponsoring brands representing every consumer vertical, will converge in ... cutting edge conversation, and a “selfiebration” of social technology. ...
    Breaking Medicine News(10 mins):Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2Health News:VCU receives grant to study molecular marks left by childhood adverse experiences 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 3Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 4
    ... 8 A woman in the United,States is ... finding,breast cancer at an early stage greatly improves ... most important woman in all our lives, our,mothers, ... celebrating,Mother,s Day by involving the culinary community and ...
    ... Hospital buildings can heal,according to the first ... the,physical environment on child patients in health care ... through the,Physical Environment is produced by the National ... partnership with the Center,for Health Design. Findings from ...
    ... 7 As the result of San ... chapters, the,North-American Interfraternity Conference supports the decisions ... officials to hold those,responsible parties accountable for ... will continue to collaborate with our member ...
    ... May 7 The top of the Empire State ... Picchu. James Chippendale is a,leukemia survivor and co-founder of ... concerts in high locations to,raise funds for cancer centers ... with a very aggressive form of,leukemia. His doctors gave ...
    ... 7 Oracle Healthcare,Acquisition Corp. (the "Company") (OTC ... approve the dissolution of the Company and,its proposed ... proxy,statement dated April 16, 2008, at the special ... As previously announced, the Company has set May ...
    ... COLUMBIA, Mo. Telehealth, using telecommunication technology to ... improve the delivery and availability of health care ... found that patients who received a telehealth intervention ... rates when compared to patients who received traditional ...
    Cached Medicine News:Health News:Celebrity Chefs and America's Restaurants Cook for the Cure This Mother's Day 2Health News:Celebrity Chefs and America's Restaurants Cook for the Cure This Mother's Day 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4Health News:James Chippendale Climbs the Mountain of Life 2Health News:Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 2Health News:Patients with chronic illness benefit from telehealth intervention 2